Amir Aliy Talasaz, Co-Founder and Co-CEO, Guardant Health : Yeah, so I think most likely within the next quarter, we should be ready to submit for breast and potentially IO therapy monitoring. And then sometime maybe end of the year is when we would at their earliest potentially be over the finish line from a Medicare reimbursement decision, hopefully a positive one. Then same thing, and that might move into the beginning of next year. But yeah, we're very encouraged by the data, by performance we're seeing from the tests. When you think about those three indications, CRC, breast and IO monitoring, those three make up the largest of the MRD indications and would then provide a very strong base for that franchise for us.